Receiving lorlatinib as first-line treatment for advanced NSCLC ALK-positive, already prescribed and administered by the patient's treating oncologist as standard of care at the time of study enrollment. This study does not initiate lorlatinib therapy or assign lorlatinib dosing; participants must already be receiving lorlatinib prior to enrollment
You may not be if
Known hypersensitivity to GLP-1 agonists.
Active, unstable psychiatric illness; current suicidal ideation
Severe organ dysfunction or systemic illness.
Anorexia nervosa
History of pancreatitis
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Current use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) or glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) \[GLP-1 RA/GIP\] co-agonist use within the last 90 days prior to screening
Current anti-obesity medication use (other than GLP-1 RA) or dipeptidyl peptidase-4 (DPP4) inhibitor use or use within the last 30 days prior to screening
Pregnant, breastfeeding or planning pregnancy
Clareo Health | Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
